These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28226264)

  • 1. Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine.
    Monroy-Jaramillo N; Rodríguez-Agudelo Y; Aviña-Cervantes LC; Roberts DL; Velligan DI; Walss-Bass C
    J Psychiatr Res; 2017 Jul; 90():26-30. PubMed ID: 28226264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere length in subjects with schizophrenia, their unaffected siblings and healthy controls: Evidence of accelerated aging.
    Czepielewski LS; Massuda R; Panizzutti B; da Rosa ED; de Lucena D; Macêdo D; Grun LK; Barbé-Tuana FM; Gama CS
    Schizophr Res; 2016 Jul; 174(1-3):39-42. PubMed ID: 27131910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocyte telomere length in patients with schizophrenia: A meta-analysis.
    Polho GB; De-Paula VJ; Cardillo G; dos Santos B; Kerr DS
    Schizophr Res; 2015 Jul; 165(2-3):195-200. PubMed ID: 25975826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.
    Bai YM; Chen TT; Liou YJ; Hong CJ; Tsai SJ
    Schizophr Res; 2011 Feb; 125(2-3):179-86. PubMed ID: 21185157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
    Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
    J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
    Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
    Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
    Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L
    Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
    Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
    J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
    Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
    Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature.
    Kluge M; Schacht A; Himmerich H; Rummel-Kluge C; Wehmeier PM; Dalal M; Hinze-Selch D; Kraus T; Dittmann RW; Pollmächer T; Schuld A
    Schizophr Res; 2014 Jan; 152(1):255-60. PubMed ID: 24315135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.
    Lu ML; Wang TN; Lin TY; Shao WC; Chang SH; Chou JY; Ho YF; Liao YT; Chen VC
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():47-50. PubMed ID: 25496829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolongation of clozapine-induced leukopenia with olanzapine treatment.
    Sayin A; Cosar B
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):958-9. PubMed ID: 16631295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.
    Weinbrenner S; Assion HJ; Stargardt T; Busse R; Juckel G; Gericke CA
    Pharmacopsychiatry; 2009 Mar; 42(2):66-71. PubMed ID: 19308881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.